Undisclosed 2+1 MUC16 TCE / Innovent Biologics - LARVOL DELTA

Topic: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy (PRNewswire) - "Innovent Biologics...announces that preclinical data...from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025....Compared to the benchmark molecule, this MUC16 TCE showed limited T cell binding and activation without MUC16, minimizing off-target activity. This 2+1 format MUC16 TCE also showed a favorable pharmacokinetics profile in mice. Functionally, systemic administration of this MUC16 TCE showed superior anti-tumor efficacy, with undetectable toxicity, in xenograft models."

Preclinical • Solid Tumor

A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy (AACR 2025) - "Indeed, combination of TCE with other therapies, e.g. ADC, chemotherapy, PD1/PDL1 mAb, are being tested clinically. Together, our pre-clinical data demonstrated that a 2+1 MUC16 TCE elicits potent anti-tumor efficacy and minimized off-target T cell activation, with potential to deliver benefits to ovarian cancer patients and patient with other MUC16-positive cancer."

Clinical • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • MUC16

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting (PRNewswire) - "Innovent Biologics...announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025."

Preclinical • Oncology